EA201992831A1 - Пиримидиновое соединение - Google Patents

Пиримидиновое соединение

Info

Publication number
EA201992831A1
EA201992831A1 EA201992831A EA201992831A EA201992831A1 EA 201992831 A1 EA201992831 A1 EA 201992831A1 EA 201992831 A EA201992831 A EA 201992831A EA 201992831 A EA201992831 A EA 201992831A EA 201992831 A1 EA201992831 A1 EA 201992831A1
Authority
EA
Eurasian Patent Office
Prior art keywords
seizure
pyrimidine compound
formula
epileptic
untreatable
Prior art date
Application number
EA201992831A
Other languages
English (en)
Other versions
EA038907B1 (ru
Inventor
Томоити Синохара
Син Ивата
Кента Араи
Нобуаки Ито
Масаки Судзуки
Original Assignee
Оцука Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оцука Фармасьютикал Ко., Лтд. filed Critical Оцука Фармасьютикал Ко., Лтд.
Publication of EA201992831A1 publication Critical patent/EA201992831A1/ru
Publication of EA038907B1 publication Critical patent/EA038907B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Abstract

Настоящее изобретение предусматривает новое пиримидиновое соединение, представленное формулой (I), и его соль[в формуле символы определены в описании], которые являются пригодными для лечения, предупреждения и/или диагностики припадка и т.п. при заболевании, предусматривающем эпилептический припадок или судорожный припадок (в том числе припадок с множественной лекарственной устойчивостью, припадок, не поддающийся лечению, острый симптоматический припадок, фебрильный припадок и эпилептическое состояние), а также их медицинское применение.
EA201992831A 2017-05-31 2018-05-31 Пиримидиновое соединение EA038907B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/JP2017/020322 WO2018220762A1 (ja) 2017-05-31 2017-05-31 ピリミジン化合物
PCT/JP2018/020997 WO2018221667A1 (en) 2017-05-31 2018-05-31 Pyrimidine compound

Publications (2)

Publication Number Publication Date
EA201992831A1 true EA201992831A1 (ru) 2020-03-30
EA038907B1 EA038907B1 (ru) 2021-11-08

Family

ID=62685028

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992831A EA038907B1 (ru) 2017-05-31 2018-05-31 Пиримидиновое соединение

Country Status (24)

Country Link
US (3) US10800758B2 (ru)
EP (1) EP3630729B1 (ru)
JP (1) JP6739653B2 (ru)
KR (1) KR20200011962A (ru)
CN (1) CN110603248B (ru)
AU (1) AU2018277949B2 (ru)
BR (1) BR112019023988A2 (ru)
CA (1) CA3064176A1 (ru)
CY (1) CY1125073T1 (ru)
DK (1) DK3630729T3 (ru)
EA (1) EA038907B1 (ru)
ES (1) ES2901452T3 (ru)
HR (1) HRP20211913T1 (ru)
HU (1) HUE056942T2 (ru)
IL (1) IL270579B2 (ru)
LT (1) LT3630729T (ru)
MX (1) MX2019014384A (ru)
PH (1) PH12019502639A1 (ru)
PL (1) PL3630729T3 (ru)
PT (1) PT3630729T (ru)
SA (1) SA519410563B1 (ru)
SI (1) SI3630729T1 (ru)
TW (2) TW202346283A (ru)
WO (2) WO2018220762A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6870064B2 (ja) * 2018-11-30 2021-05-12 大塚製薬株式会社 ピリミジン化合物の医薬用途
EP3887358A1 (en) * 2018-11-30 2021-10-06 Otsuka Pharmaceutical Co., Ltd. Heterocyclic compounds for the treatment of epilepsy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009559A2 (en) * 2002-07-18 2004-01-29 Queen's University At Kingston Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents
EA019970B8 (ru) 2009-12-11 2014-11-28 Отифони Терапеутикс Лимитед Производные имидазолидиндиона
MX2012008346A (es) * 2010-01-25 2012-11-12 Chdi Foundation Inc Determinados inhibidores de cinurenina-3-monooxigenasa, composiciones farmceuticas y metodos de uso de los mismos.
BR112013013914B1 (pt) * 2010-12-06 2021-10-26 Autifony Therapeutics Limited Compostos derivados de hidantoína úteis como inibidores de kv3, usos dos referidos compostos e composição farmacêutica compreendendo os mesmos
WO2012168710A1 (en) * 2011-06-07 2012-12-13 Autifony Therapeutics Limited Hydantoin derivates as kv3 inhibitors
WO2013016488A1 (en) * 2011-07-28 2013-01-31 Celia Dominguez Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
KR20140098850A (ko) 2011-12-06 2014-08-08 오티포니 세라피틱스 리미티드 Kv3 억제제로서 유용한 하이단토인 유도체
GB201521751D0 (en) * 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses

Also Published As

Publication number Publication date
AU2018277949B2 (en) 2021-11-18
EA038907B1 (ru) 2021-11-08
TWI808974B (zh) 2023-07-21
LT3630729T (lt) 2022-01-10
KR20200011962A (ko) 2020-02-04
CY1125073T1 (el) 2023-03-24
EP3630729A1 (en) 2020-04-08
SI3630729T1 (sl) 2022-01-31
CN110603248B (zh) 2023-07-04
US10800758B2 (en) 2020-10-13
EP3630729B1 (en) 2021-11-03
IL270579A (ru) 2019-12-31
JP6739653B2 (ja) 2020-08-12
PL3630729T3 (pl) 2022-01-24
WO2018221667A1 (en) 2018-12-06
PH12019502639A1 (en) 2020-06-08
JP2020503334A (ja) 2020-01-30
US20230138411A1 (en) 2023-05-04
HRP20211913T1 (hr) 2022-03-04
CN110603248A (zh) 2019-12-20
CA3064176A1 (en) 2018-12-06
SA519410563B1 (ar) 2022-07-25
HUE056942T2 (hu) 2022-03-28
TW201902890A (zh) 2019-01-16
PT3630729T (pt) 2021-12-16
MX2019014384A (es) 2020-01-23
ES2901452T3 (es) 2022-03-22
DK3630729T3 (da) 2021-12-13
IL270579B2 (en) 2023-08-01
BR112019023988A2 (pt) 2020-06-30
IL270579B1 (en) 2023-04-01
TW202346283A (zh) 2023-12-01
US20200017476A1 (en) 2020-01-16
WO2018220762A1 (ja) 2018-12-06
AU2018277949A1 (en) 2019-12-12
US20200399245A1 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
EA201791070A1 (ru) Способы получения ингибиторов ask1
EA201690066A1 (ru) Соединения пиримидиндиона
EA201690952A1 (ru) Пиразол для лечения аутоиммунных расстройств
EA201791011A1 (ru) 3-ЗАМЕЩЕННЫЕ 5-АМИНО-6H-ТИАЗОЛО[4,5-d]ПИРИМИДИН-2,7-ДИОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИРУСНЫХ ИНФЕКЦИЙ
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
EA201790764A1 (ru) Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
EA201491283A1 (ru) Ингибитор регулирующей апоптотические сигналы киназы
EA201890338A1 (ru) Оксадиазольные производные, пригодные в качестве ингибиторов hdac
EA201791656A1 (ru) Соединения 4-метилсульфонилзамещенной пиперидинмочевины для лечения дилатационной кардиомиопатии (dcm)
EA201171200A1 (ru) Полиморфы элтромбопага и солей элтромбопага, а также способы их получения
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
EA201391019A1 (ru) Соединения и способы для модуляции киназ, а также показания к их применению
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA201491936A1 (ru) Азотсодержащее гетероциклическое соединение
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
EA202091777A1 (ru) Аминопирролотриазины в качестве ингибиторов киназы
EA201590653A1 (ru) Терапевтическое средство при дислипидемии
EA201491276A1 (ru) Новые производные бензилсульфонамида, подходящие для применения в качестве ингибиторов mogat-2
EA201790912A1 (ru) Гетероциклическое соединение
PH12017502069A1 (en) Method for treating coffee rust, citrus black spot, citrus scab and banana black sigatoka diseases
EA201992233A1 (ru) Соединения изоксазолкарбоксамида и их применение